GlassScriptPhysician profile
Michael Farhangian
NPI 1346690138
$3,226.46
in general payments reported to CMS, 2019-2025
15 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $149 · 2021: $586 · 2022: $528 · 2023: $641 · 2024: $300 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,273.99 | 2020-2025 | |
| Galderma Laboratories, L.P. | $353.47 | 2025 | Nemluvio |
| Amgen INC. | $294.53 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $254.42 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $178.57 | 2023 | Vtama |
| Incyte Corporation | $162.71 | 2021-2025 | Opzelura |
| Abbott Laboratories | $150.00 | 2024 | Freestyle Libre 3 |
| Janssen Biotech, INC. | $142.34 | 2023 | Tremfya |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Stemline Therapeutics INC. | $118.73 | 2021 | |
| Pfizer INC. | $53.37 | 2025 | |
| Sun Pharmaceutical Industries INC. | $43.37 | 2025 | |
| Lilly USA, LLC | $40.98 | 2025 | Taltz, Ebglyss |
| Verrica Pharmaceuticals INC. | $20.42 | 2025 | Ycanth |
| Leo Pharma INC. | $14.56 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Farhangian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.